FORTIS - Fundamental Analysis: Financial Health & Valuation
← Back to ListKey Parameters
⭐ Fundamental Rating: 3.0
✅ Positive
Fortis Healthcare demonstrates strong profit growth of 382% year-over-year, driven by increased PAT to 33 Cr this quarter. The company maintains a relatively conservative debt-to-equity ratio of 0.23.
⚠️ Limitation
A high P/E ratio of 366 suggests the stock is significantly overvalued relative to its earnings and industry peers. The PEG ratio of 6.88 further emphasizes this valuation concern, indicating that investors are paying a premium for expected growth.
📉 Company Negative News
None found
📈 Company Positive News
Religare Broking Ltd has issued a target price of Rs. 1040, potentially creating upside pressure on the stock if achieved. Northern TK Venture maintains a significant shareholding in Fortis Healthcare.
🏭 Industry
The healthcare sector is experiencing robust growth due to rising healthcare expenditure and an aging population globally. However, it's also characterized by intense competition, regulatory scrutiny, and potential cost pressures.
🧾 Conclusion
Given the substantial undervaluation indicated by the low P/E ratio compared to the industry average, a reasonable entry zone would be between 850 ₹ – 900 ₹. Long-term holding guidance recommends maintaining exposure, acknowledging the high valuation but contingent on sustained profit growth and management execution. The stock presents a moderate risk/reward profile suitable for investors with a long-term horizon.